IU School of Dentistry gets OK for $21.6M expansion
The IU Board of Trustees gave unanimous approval to the 45,000-square-foot addition to the school at IUPUI. It is expected to open in 2020.
The IU Board of Trustees gave unanimous approval to the 45,000-square-foot addition to the school at IUPUI. It is expected to open in 2020.
Dr. Bill Tierney, who has led the Regenstrief medical informatics research operation for five years, will become chair of the department of population health at the Dell Medical School at the University of Texas at Austin.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Concerns about serious side effects, including fainting, complicate discussions about whether to cover Sprout Pharmaceuticals' Addyi.
The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.
Biotech drugmaker Amgen will pay $71 million to settle an investigation into illegal marketing of its drugs Aranesp and Enbrel, ending an investigation by 48 states and Washington, D.C.
The plan is to create an agency that gives undergrads practical experience in insuring everything from campus buildings to Butler bulldog mascot Blue III, known as Trip.
Catheter Research Inc.—which makes single-use medical devices, such as catheters—plans a $4.8 million expansion that will relocate its headquarters to larger space on the northwest side.
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Some patients who had their personal information compromised by a data breach at an Indiana medical software company are having trouble signing up for two years of free credit monitoring and identity protection.
The federal government says it wants Lance Armstrong's medical records from his 1996 cancer treatments because they could prove just how far he was willing to go to conceal performance-enhancing drug use from the public and his sponsors.
A jury found Lilly isn't liable for withdrawal symptoms experienced by a woman who quit the antidepressant Cymbalta. The verdict may give the drugmaker leverage in fending off more than 5,000 other lawsuits over the drug.
Dr. John Sturman overprescribed narcotics to patients at a clinic he operated at Indiana University Hospital, Marion County prosecutors contend. The deaths occurred in 2010 and 2011.
Indiana University Health has agreed to revoke disciplinary actions against two nurses who tried to organize a union at IU Health’s Methodist Hospital earlier this year, the United Steelworkers announced.
With this year’s bill estimated at $37 billion and counting, perhaps the sheer cost of cleaning up after IT security breaches at health care organizations will spur the industry to find a bandage for its hemorrhaging computer systems.
A Chicago company that won a massive judgment against Indianapolis businessman Alan Symons, his family and related companies accuses the 66-year-old of “hide-the-ball” conduct.
The Indianapolis-based transportation insurer said the decreases in second-quarter revenue were part of a strategic shift to reduce some lines of insurance.
The government wants to see Lance Armstrong’s medical records from his treatments for cancer as it attempts to recover millions of dollars in sponsorship money paid to his cycling teams.
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
The company said the exposed information includes names, addresses, birthdates, Social Security numbers and health records.